Genfit S.A. | Mutual Funds
Mutual Funds that own Genfit S.A.
Oppenheimer International Small Company Fund
449,840
1.44%
0
0.12%
02/28/2018
Vanguard Total International Stock Index Fund
413,062
1.33%
22,474
0%
07/31/2018
Government Pension Fund - Global (The)
334,841
1.07%
-89,295
0%
12/31/2017
JPMorgan Funds - Global Healthcare Fund
188,842
0.61%
0
0.18%
05/31/2018
AXA Framlington Biotech Fund
175,174
0.56%
0
0.68%
02/28/2018
Vanguard Developed Markets Index Fund
160,422
0.52%
0
0%
07/31/2018
Alken Fund - European Opportunities
157,888
0.51%
1,248
0.14%
12/31/2017
Rhenman & Partners Fund - Healthcare Equity L/S
153,369
0.49%
-35,221
0.3%
12/31/2017
iShares Core MSCI EAFE ETF
143,063
0.46%
0
0.01%
09/06/2018
iShares MSCI EAFE Small Cap ETF
142,660
0.46%
0
0.04%
09/06/2018
| Address |
Parc Eurasante
Loos Nord-Pas-de-Calais 59120
France
|
|
Employees
|
- |
| Website |
http://www.genfit.com |
| Updated |
07/08/2019 |
| Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. Its research and development efforts are focused on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. |
